ReviewCurrent hematologic malignancy reports2013
Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.
Review in Current hematologic malignancy reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06666153 (A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases), which is not on this map. Cited by 131 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of Therapeutic Immunological Agent for EBV Lymphoproliferative Diseases
Who cites it
131 citing papers in PubMed, 2 syntheses or guidelines pooled it, 313 citations in OpenAlex.
- Role of mTOR Inhibitors in Pediatric Liver Transplant Recipients: A Systematic Review.Paediatric drugs · 2024Pooled it
- Systematic review and meta-analysis of post-transplant lymphoproliferative disorder in lung transplant recipients.Clinical transplantation · 2018Pooled it
- Tabelecleucel for EBV+ PTLD after allogeneic HCT or SOT in a multicenter expanded access protocol.Blood advances · 2024Trial
- Posttransplant Malignant Neoplasms in Solid Organ Transplant Recipients.JAMA network open · 2026Article
- Kidney disease and transplantation in childhood cancer survivors.Pediatric nephrology (Berlin, Germany) · 2026Review
- Global Epidemiology of Post-Transplant Lymphoproliferative Disorder (PTLD) in Hematopoietic Stem Cell Transplantation (HSCT): A Systematic Review and Meta-Analysis of Incidence, Subtypes, Risk Factors, and Beyond.Journal of clinical medicine · 2026Review
- Article
- Central nervous system post-transplant lymphoproliferative disorder relapse after pediatric liver transplantation: a case report and literature review.Translational pediatrics · 2026Article
- Progressive Multifocal Leukoencephalopathy Initially Considered as Central Nervous System Involvement of Post-Transplant Lymphoproliferative Disorder: The Critical Role of Contrast Enhancement on Magnetic Resonance Imaging.Internal medicine (Tokyo, Japan) · 2026Article
- Post-transplant Lymphoproliferative Disorder Successfully Treated with Pola-R-CHP and Achieved Long-term Remission.Internal medicine (Tokyo, Japan) · 2026Article
- Clinical presentation, management, and outcomes of post-transplant lymphoproliferative disorder in renal and pancreas transplantation: a 22-year experience.Frontiers in transplantation · 2026Article
- A Case of Epstein-Barr Virus-Associated Transplanted Kidney Post-Transplant Lymphoproliferative Disorder Complicated by Hemophagocytic Lymphohistiocytosis, Six Years after Transplantation.Surgical case reports · 2026Article
- Early Posttransplant Lymphoproliferative Disorder and Cryptosporidiosis After Liver Transplantation.Case reports in medicine · 2026Article
- Treatment of post-transplant lymphoproliferative disorders in kidney transplant recipients: a single-center retrospective analysis.International journal of hematology · 2025Article
- Cutaneous Epstein-Barr virus-positive polymorphous posttransplantation lymphoproliferative disorder responding to rituximab.JAAD case reports · 2025Article
- Peritoneal lymphomatosis as a rare entity of post-transplant lymphoproliferative disorder after kidney transplantation: a case report.CEN case reports · 2025Article
- Post-Transplant Lymphoproliferative Disorder Presenting as Biventricular Failure After Heart Transplantation.JACC. Case reports · 2025Article
- Tabelecleucel in Post-transplant Epstein-Barr Virus-Associated Lymphoproliferative Disease: Patient and Oncologist Perspectives.Advances in therapy · 2025Article
- Article
- Molecular mechanisms of viral oncogenesis in haematological malignancies: perspectives from metabolic reprogramming, epigenetic regulation and immune microenvironment remodeling.Experimental hematology & oncology · 2025Review
71 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Post-transplant lymphoproliferative diseases (PTLD) are heterogeneous lymphoid disorders ranging from indolent polyclonal proliferations to aggressive lymphomas that complicate solid organ or hematopoietic transplantation. Risk factors for PTLD include viral infections, degree of immunosuppression, recipient age and race, allograft type, and host genetic variations. Clinically, extra-nodal disease is common including 10-15 % presenting with central nervous system (CNS) disease. Most PTLD cases are B cell (5-10 % T/NK cell or Hodgkin lymphoma), while over one-third are EBV-negative. World Health Organization (WHO) diagnostic categories are: early lesions, polymorphic, and monomorphic PTLD; although in practice, a clear separation is not always possible. Therapeutically, reduction in immunosuppression remains a mainstay, and recent data has documented the importance of rituximab +/- combination chemotherapy. Therapy for primary CNS PTLD should be managed according to immunocompetent CNS paradigms. Finally, novel treatment strategies for PTLD have emerged, including adoptive immunotherapy and rational targeted therapeutics (e.g., anti-CD30 based therapy and downstream signaling pathways of latent membrane protein-2A).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.